INTRODUCTION:

Tobacco consumption poses a significant health risk, predisposing users to noncommunicable diseases and contributing to premature mortality globally. Smokeless tobacco and cigarette smoking together account for 6 and 5% of disability-adjusted life years (DALYs) caused by tobacco use, respectively, and are responsible for almost 8 million deaths annually.

Despite a downward trend in global tobacco use since 1990³, the prevalence remains alarmingly high, posing a formidable challenge to public health efforts. Variations in tobacco smoking prevalence are evident across different demographic groups, including variations based on race, ethnicity, and education level. Despite concerted efforts at national and state levels to curb tobacco use, It continues to threaten the health and well-being of individuals, especially those uncovered the areas with smoking².

Globally, tobacco-related mortality affects approximately one in ten adults, resulting in around five million deaths annually. Developing countries bear a disproportionate burden, with 2.41 million deaths attributed to tobacco, compared to 2.43 million in developed countries. Additionally, about 33% of adults are frequently exposed to second-hand tobacco smoke², further exacerbating the public health impact of tobacco use. Despite the significant role pharmacists could play in tobacco cessation efforts, they have received comparatively less attention in community healthcare settings. However, pharmacists are uniquely positioned as accessible healthcare providers and can effectively initiate behaviour change among patients, particularly in underserved populations with a high incidence of tobacco-related diseases⁴.

Research has demonstrated that pharmacists can be a cost-effective part of tobacco cessation programs. Additionally, specialized training in tobacco cessation counselling improves the likelihood that pharmacists will engage patients in tobacco use and boosts patient satisfaction with counselling sessions. However, despite these benefits, studies suggest that pharmacists often fail to regularly address tobacco use with their patients^5-8.

In India, diseases associated with tobacco use claim the quality of life of around a million people annually. A comprehensive strategy is required to reduce significant impact of tobacco-related illness and mortality. This strategy should encompass efforts to prevent tobacco use initiation in non-users, as well as encourage cessation among those who currently use tobacco. If they do not quit, more than half of current tobacco consumers would eventually die from tobacco-related diseases. Furthermore, reduction in tobacco use is mandatory for the prevention of 180 million tobacco-related deaths among adults by 2020. Tobacco cessation is the only effective short-term strategy to reduce tobacco-related mortality and morbidity. Hence, it is necessary to offer comprehensive cessation programs to those who are currently using tobacco^1,9.

The World Health Organization's(WHO) India Country Office and Indian Ministry of Health and Family Welfare recognized an urgent requirement to quit smoking and established 13 tobacco cessation clinics (TCCs) in 2002 subsequently expanding to 19. These clinics established to establish cessation plans for smokeless tobacco users and cigarette smokers, collect information on tobacco cessation techniques and determine whether those strategies could be successfully scaled. During initial 5 years, these clinics served 34,741 tobacco users, with initial data at baseline collected from 23,320 individuals¹⁰. Notably, 69% of users received behavioural interventions only, while the remaining 31% received a combination of behavioural interventions and pharmacotherapy. After six weeks, 14% of individuals reported complete tobacco cessation, while another 22% reported harm reduction, indicating a reduction in tobacco use by at least 50% compared to baseline. However, a significant limitation of these clinics was the limited number of tobacco users accessing them, particularly from rural areas, highlighting the need for broader outreach efforts to underserved populations^9,10.

In India, unassisted smoking cessation rates are notably low compared to Western countries. Typically, individuals in India tend to quit tobacco use only after experiencing tobacco-related diseases. Therefore, tobacco use must be addressed by physicians and other healthcare providers as a serious public health issue. With support of Fogarty International Centre of US National Institutes of Health, Quit Tobacco International (QTI) initiative launched project for incorporating tobacco cessation interventions into undergraduate medical curriculum in India and Indonesia given that it recognized that quitting tobacco among the general public frequently follows quitting among healthcare professionals. Incorporating 5 'A's (Ask, Advise, Assess, Assist, Arrange) and 5 'R's (Relevance, Risks, Rewards, Roadblocks, Repetition), the initiative's primary objective is to give medical students the fundamental skills they require to encourage patients to quit smoking. This project in India comprised development, piloting, implementation, and assessment of 15 course modules across many departments of 5 medical colleges in the states of Kerala and Karnataka.^1,11,12

Numerous countries have implemented diverse policies aimed at reducing tobacco use. However, tobacco cessation remains a complex process, necessitating comprehensive approaches¹³. Healthcare professionals perform an essential function in aiding smoke cessation initiatives. Framework Convention on Tobacco Control (FCTC) had been introduced by WHO in 2003 in response to the global tobacco pandemic¹⁴. 181 nations have ratified this convention, which attempts to limit tobacco use globally by lowering the supply and demand for tobacco products. As part of its strategy, WHO introduced the MPOWER measures, which focus on six key actions to fight the tobacco epidemic: Tracking tobacco use, shielding individuals from tobacco smoke, providing quitting support, alerting regarding risk of tobacco, enforcing tobacco advertising, promotion, and sponsorship bans, and increasing taxes on tobacco products. Significant information about the implementation of these policies in India may be identified in Global Adult Tobacco Survey (GATS) data. However, even with these efforts, additional effort is required among people 15 and older to accomplish global voluntary goal of 30% decrease in tobacco use by 2025. This highlights the ongoing challenges and the urgent need for continued efforts in tobacco control and cessation^15,16.

Forms of Tobacco:^17,18

Tobacco is available in both smoking and smokeless forms. Bidis, hand-rolled and manufactured pipes, cigarettes, sticks, cigars, water pipes, hookahs, and other manufactured locally smoking accessories including dhumti, chuttas, kreteks, and chillum are examples of smoking tobacco products. Conversely, Tobacco products without smoke, often called spit tobacco, cover a wide range of chewing tobacco, including betel quid with tobacco, paan masala, khaini, gutkha, and mainpuri tobacco, including other items that include gudakhu, mishri, bajjar, mawa, gul, and snuff.

Tobacco Dependence:^19,20

The International Classification of Diseases (ICD-10) has recognized tobacco dependence as disease, that is characterized by range of physical, behavioural, and cognitive symptoms that develop with continued tobacco use. These symptoms often feature a significant presence of the urge to engage in tobacco consumption, an inability to control its use, continued use despite adverse effects, prioritizing tobacco use over other activities along with responsibilities, enhanced tolerance, and in some cases, Abstinence symptoms. Nicotine, which is efficiently absorbed through the respiratory tract, buccal mucosa, and skin, plays a pivotal role in the onset of tobacco dependence. Symptoms of nicotine dependence can affect the central nervous system, leading to irritability, anger, impatience, difficulty concentrating, and cravings—factors that often contribute to relapses among smokers trying to quit.

Tobacco quitting strategies follow Healthcare practice standards, notably employing the 5 "A's" and 5 "R's" approach:

5 A's—Ask, Advise, Assess, Assist, and Arrange and 5 R's—Relevance, Risk, Rewards, Repetition, and Roadblocks represent brief, 5 to 15-minute strategy that has shown effective worldwide tobacco cessation efforts. Using 5 R's, clinicians can encourage patients to consider quitting by addressing the Significance of cessation, Risks associated with continued use, Benefits of quitting, potential Obstacles to success, and the importance of Repetition in reinforcing the message²⁴.

Overview: Tobacco Cessation Brief Clinical Intervention

Figure 1: Clinical Intervention on Tobacco Cessation^22,23

The approach to tobacco cessation involves the following steps:

1. Relevance: Motivate the patient to express the personal significance of quitting to them. Understanding the individual reasons for quitting can enhance motivation and commitment to the cessation process.

2. Risks: Assist the patient in identifying the harmful effects of tobacco use. By recognizing risks associated with tobacco use, individuals may become more motivated to quit to reduce these health hazards.

3. Rewards: Guide the patient to explore the advantages of quitting tobacco. Focusing on positive outcomes of quitting, including greater health benefits, financial savings, and enhanced quality of life, can reinforce motivation for cessation.

4. Roadblocks: Assist the patient in identifying barriers or impediments to quitting. Addressing challenges such as withdrawal symptoms, social influences, and stressors can help individuals develop coping strategies and overcome obstacles to cessation.

5. Repetition: Emphasize the importance of repetition in the motivational intervention. It should be reiterated to the patient during each interaction with a clinician, especially for those who may initially lack motivation. Additionally, individuals who have experienced previous unsuccessful quit attempts should be informed that multiple attempts are common before achieving successful cessation, normalizing the process and promoting persistence in cessation efforts.

Pharmacotherapy^25,26

Tobacco cessation resources are broadly classified into 2 categories:

· Nicotine replacement therapy(NRT)

· Non-nicotine replacement therapy

Nicotine replacement therapy:

NRT intends to relieve nicotine withdrawal symptoms and lower the smoker's craving for tobacco. Various NRT products are offered, including:

1. Nicotine Gum: Chewing gum containing nicotine that is absorbed through the oral mucosa.

2. Nicotine Patch: Transdermal patches that deliver consistent nicotine dose transferred via skin.

3. Nasal Sprays: Sprays containing nicotine that are administered into the nostrils for rapid absorption.

4. Nasal Inhaler: Devices that deliver nicotine vapor to be inhaled through the nose.

5. Nicotine Sublingual Tablets and Lozenges: Tablets or lozenges containing nicotine that dissolve under the tongue for absorption.

6. Nicotine Vaccine: A vaccine that stimulates immune system for producing antibodies against nicotine, reducing its effects.

These NRT products act quickly, with blood nicotine levels reaching their peak within about 20 minutes of use. They offer a safer substitute for smoking, offering nicotine without the dangerous toxins found in tobacco smoke, assisting individuals in progressively decreasing their nicotine dependency and finally quitting smoking.

Non-nicotine replacement therapy:

First Line of Drugs:

· Varenicline

· Bupropion

Second Line of Drugs:

· Clonidine

· Nortriptyline

It has been found that smoking cessation methods, such as nicotine replacement therapies and herbal alternatives, offer several advantages over traditional smoking habits. Herbal remedies contain natural compounds that may help reduce cravings and withdrawal symptoms. There is growing interest in herbal options for quitting smoking, as they are often reported to have fewer side effects and lower toxicity compared to synthetic pharmaceutical treatments⁴⁰.

Benefits of Quitting^27,28

Quitting smoking offers numerous health benefits, regardless of age or duration of smoking. Some key benefits include:

1. Health Benefits and Improved Quality of Life: The impact of quitting smoking enhances overall health and well-being, leading to a better quality of life.

2. Reduced Risk of Premature Death: Quitting smoking can significantly reduce the chance of untimely death, potentially extending life expectancy by as much as 10 years.

3. Lower Chance of harmful health effects: Ceasing tobacco use decreases the risk of various harmful health effects, that includes cancer, chronic obstructive pulmonary disease (COPD), cardiovascular diseases, and poor reproductive health results.

4. Beneficial for Those with Existing Health Conditions: Quitting smoking can benefit individuals diagnosed with conditions particularly coronary heart disease(CHD) or COPD by reducing symptoms and slowing disease progression.

5. Positive Effects During Pregnancy: Quitting smoking during pregnancy benefits both the mother and the fetus, reducing the risk of complications and promoting better health outcomes for both.

6. Financial Relief: Quitting smoking can alleviate the financial burden associated with purchasing cigarettes and treating smoking-related health conditions, benefiting individuals, Healthcare services, and society at large.

Stopping smoking earlier in life offers the greatest Wellness benefits, but stopping at any age still offers significant improvements. Even those who have smoked heavily or for many years can see positive changes in their health after quitting. Additionally, quitting smoking helps protect non-smokers- such as family members, coworkers, and friends- from the harmful effects of second-hand smoke³¹. The risk of cardiovascular-related deaths is significantly higher in smokers, but the underlying mechanisms are not fully understood. Coordinated interventions and consistent monitoring across various healthcare settings could potentially help reduce this risk. There is an urgent need to develop and implement effective programs aimed at reducing smoking-related health issues, and we argue that healthcare professionals, especially in mental health and addiction services, should play a more active role in this critical effort³⁶.

Smoking cessation is crucial for maintaining health and preventing long-term damage caused by tobacco use. Smoking leads to oxidative stress, which damages the body at a cellular level, increasing risk of diseases that includes cancer and heart disease. Just as antioxidants act as the body's defence against oxidative damage, quitting smoking can significantly reduce this harm. Natural methods, such as herbal remedies and lifestyle changes, can support the body in repairing the damage caused by smoking. It's essential to incorporate healthier habits and natural products, such as fruits and vegetables rich in antioxidants, to help combat the effects of smoking and improve overall health⁴².

Gradual health improvements after quitting smoking:³²

Table 1: Health benefits of quitting smoking³²

Time after quitting	Health benefits
Minutes	Heart rate slows down.
24hours	Blood nicotine levels have been reduced to zero.
Several days	Blood's carbon monoxide level decrease to non-smoker level.
1-12months	Coughing and respiratory discomfort decrease.
1-2years	Heart attack risk declines rapidly.
3-6years	Reduces an additional risk of CHD by half.
5-10years	The increased risk of mouth, throat, and voice box cancers is halved. Stroke risk is reduced.
10years	Lung cancer risk is reduced by half after 10-15 years. Bladder, oesophagus, and kidney cancer risks are lowered.
15years	CHD risk decreases to level of non-smokers.
20years	Risk of throat, voice box, and mouth cancers decrease to about same level as for nonsmokers. Pancreatic cancer risk to that of nonsmokers. An additional risk of cervical cancer is reduced by approximately 50%.

Biomarkers can provide insights into the full spectrum of smoking-related diseases, from the earliest signs of harm to the most advanced stages of illness. In clinical investigations, biomarkers perform essential functions in assessing impact of smoking, helping to identify early biological changes, monitor disease progression, and evaluate the effectiveness of smoking cessation or treatment strategies³³.

Over the years, advancements in patient convenience and compliance-focused drug delivery research have led to the development of innovative delivery systems. One such system, medicated chewing gum (MCG), provides a highly convenient and patient-friendly way to administer medication. It is not only beneficial for special populations, such as children and the elderly who may have difficulty swallowing but also for the general population, including younger individuals. MCG is easy to use, can be taken discreetly anytime and anywhere, and has a pleasant taste, making it well-accepted by patients. This delivery system offers a wide range of benefits, making it an ideal alternative for smoking cessation. Medicated chewing gum can help manage cravings and withdrawal symptoms, providing an effective solution for those aiming to quit smoking^34,35,36.

CONCLUSION:

In conclusion, addressing tobacco cessation is a critical priority for public health in India and globally. Pharmacists play a crucial role as a bridge between healthcare systems and tobacco users, offering valuable support and assistance in quitting efforts. However, tobacco cessation efforts should extend beyond the pharmacy setting to encompass various healthcare environments^29,30,37. It is essential to include tobacco cessation education in medical and health professional programs to provide aspiring medical professionals with skills and expertise required to deliver cessation assistance as standard treatment. Additionally, targeted counselling sessions within specific disease management programs, such as those for diabetes and tuberculosis, can contribute to significant quit rates among tobacco users with coexisting health conditions^43,44. The complex relationship between smoking and health highlights the need for public health interventions focused on tobacco prevention and cessation. To address this issue, comprehensive measures are required to increase public awareness regarding long-term health concerns associated with smoking and to motivate consumers in refraining from or stop using tobacco products. The increasing prevalence of smoking-related diseases in society can only be decreased by coordinating efforts to encourage quitting, offer support networks, and ensure that individuals attempting to quit have access to resources³⁸. Furthermore, successful execution of tobacco regulation strategies, such as those described in the Framework Convention on Tobacco Control, holds promise for preventing tobacco initiation and promoting cessation on a broader scale⁴¹. By addressing tobacco cessation through multiple strategies and settings, India has the potential to make significant progress in reducing tobacco-related diseases and deaths, leading to improved public health outcomes across the country⁴⁵. Lifestyle changes can help prevent smoking-related health issues such as heart disease, stroke, lung disease, and cancer³⁹.

CONFLICT OF INTEREST:

There is no conflict of interest reported by the authors.

REFERENCES:

1. Tobacco cessation in India: A priority health intervention. Indian J Med Res. 2014; 139: 484-486.

2. Shaik SS, Doshi D, Kulkarni S, Tobacco Use Cessation and Prevention – A Review. Journal of Clinical and Diagnostic Research. 2016 ; 10(5): ZE13-ZE17.

3. Singh SK, Kumar S. Tobacco Use and Cessation among a Nationally Representative Sample of Men in India, 2019–2021. Journal of Smoking Cessation. 2023.

4. Hudmon KS, Corelli RL. Tobacco cessation counseling: Pharmacists’ opinions and practices. Patient Education and Counseling. 2006; 61: 152–160.

5. McGhan WF, Smith MD. Pharmacoeconomic analysis of smoking cessation interventions. Am J Health-Syst Pharm. 1996; 53: 45–52.

6. Tran MT, Holdford DA, Kennedy DT, Small RE. Modeling the cost effectiveness of a smoking-cessation program in a community pharmacy practice. Pharmacotherapy. 2002; 22:1623–31.

7. Sinclair HK, Bond CM, Lennox AS, Silcock J, Winfield AJ, Donnan PT. Training pharmacists and pharmacy assistants in the stage-of change model of smoking cessation: a randomised controlled trial in Scotland. Tob Contr. 1998; 7:253–61.

8. Aquilino ML, Farris KB, Zillich AJ, Lowe JB. Smoking-cessation services in Iowa community pharmacies. Pharmacotherapy. 2003; 23:666–73.

9. Shafey O, Eriksen M, Ross H, Mackay J. The tobacco atlas, 3rd ed.: Atlanta, Georgia, USA: American Cancer Society; 2009.

10. Murthy P, Saddichha S. Tobacco cessation services in India: recent developments and the need for expansion. Indian J Cancer. 2010; 47 (Suppl): 69-74.

11. Chapman S, MacKenzie R. The global research neglect of unassisted smoking cessation: Causes and consequences. PLoS Med. 2010; 7: e1000216.

12. Project quit tobacco international. Available from: http:// quittobaccointernational.org, accessed on October 12, 2013.

13. R. Borland, T. R. Partos, H. H. Yong, K. M. Cummings, and A. Hyland. How much unsuccessful quitting activity is going on among adult smokers? Data from the International Tobacco Control Four Country cohort survey. Addiction. 2012; 107(3): 673–682.

14. J. Chung-Hall, L. Craig, S. Gravely, N. Sansone, and G. T. Fong. Impact of the WHO FCTC over the first decade: a global evidence review prepared for the Impact Assessment Expert Group. Tobacco Control. 2019; 28(Suppl 2): s119– s128.

15. World Health Organization, WHO report on the global tobacco epidemic, 2011: warning about the dangers of tobacco: executive summary (No. WHO/NMH/TFI/11.3), World Health Organization, Geneva, 2011.

16. Y. Song, L. Zhao, K. M. Palipudi et al. Tracking MPOWER in 14 countries: results from the Global Adult Tobacco Survey, 2008–2010. Global Health Promotion. 2016;23(2_suppl): 24–37.

17. Peter S. Essentials of Preventive and Community Dentistry. 4th ed. New Delhi; Arya Medi Publishing House. 2011: 136-137.

18. Global Adult Tobacco Survey GATS India 2009-2010. Ministry of Health and Family Welfare Government of India.

19. Bhatnagar D and Jain DC. Tobacco dependence treatment Guidelines. National Tobacco Control Programme. India 2011.

20. Maseeh A and Kwatra G. A review of smoking cessation interventions. Med Gen Med. 2005; 7(2): 24.

21. Watts SA, Noble SL, Smith PO, Disco M. First-line pharmacotherapy for tobacco use and dependence. J Am Board Fam Pract. 2002; 15: 489–97.

22. CDC’s Office on Smoking and Health – CDC.gov/TobaccoHCP

23. A Practical Guide to Help Your Patients Quit Using Tobacco

24. Patients Not Ready To Make A Quit Attempt Now (The “5 R’s”), Treating Tobacco Use and Dependence, PHS Clinical Practice Guideline.

25. Galanti LM. Tobacco smoking cessation management: integrating varencline in current practice. Vasc Health Risk Manag. 2008; 4(4): 837-45.

26. Bhatnagar D and Jain DC. Tobacco dependence treatment Guidelines. National Tobacco Control Programme. India 2011.

27. U.S. Department of Health and Human Services. Smoking Cessation: A Report of the Surgeon General. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2020. [accessed 2020 May 13].

28. U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Office on Smoking and Health, 2014 [accessed 2020 May 13].

29. Kumar MS, Sarma PS, Thankappan KR. Community-based group intervention for tobacco cessation in rural Tamil Nadu, India: a cluster randomized trial. J Subst Abuse Treat. 2012; 43: 53-60.

30. Pradeep Kumar AS. Smoking cessation intervention program in Primary Health Centres in Palakkad district, Kerala. Unpublished PhD thesis, Achutha Menon Centre for Health Science Studies, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerela, India; 2009

31. Glynn TJ, Manley MW. How to help your patients stop smoking: a National Cancer Institute Manual for physicians. U.S. Department of Health and Human Services, U.S. Public Health Service, National Institutes of Health, National Cancer Institute, 1990.

32. Maguire TA, McElnay JC, Drummond A. A randomized controlled trial of a smoking cessation intervention based in community pharmacies. Addiction. 2001; 96: 325–31.

33. Pradeep Sahu, Neha Pinkalwar, Ravindra Dhar Dubey, Shweta Paroha, Shilpi Chatterjee, Tanushree Chatterjee. Biomarkers: An Emerging Tool for Diagnosis of a Disease and Drug Development. Asian J. Res. Pharm. Sci. 2011; 1(1): 9-16.

34. Mohan A. Ughade, Suraj R. Wasankar, Abhishek D. Deshmukh, Rahul M. Burghate, Kshitij B. Makeshwar. Medicated Chewing Gum: Modern Approach to Mucosal Drug Delivery. Asian J. Res. Pharm. Sci. 2012; 2(4): 150-159.

35. Kasad Pinaz A., K.S. Muralikrishna. Area Under Curve Spectrophotometric Method for Determination of Rivaroxaban in Bulk and Tablet Formulation and Its Validation. Asian J. Res. Pharm. Sci. 2013; 3 (3); 109-113.

36. Varshita Veerni Jaya Ratna, Monika Vempadapu, Raj kiran Kolakota, Vinodkumar Mugada. Risk of Cardiovascular Disease in Schizophrenia: A Mini Review. Asian J. Res. Pharm. Sci. 2019; 9(2): 131-136.

37. Rahul P. Jadhav, Manohar D. Kengar, Nikita R. Nikam, Mangesh A. Bhutkar. Tobacco Cancer: A Review. Asian J. Res. Pharm. Sci. 2019; 9(4): 276-281.

38. Geetanjali V. Nikam, Manohar D. Kengar, Navnath V. Kalyani, Amol A. Patil. Review on: Diet and its Disease. Asian Journal of Research in Pharmaceutical Sciences. 2024; 14(2):146-8.

39. Swathi. S, B. Swathi, Kasireddy Swapna, G. Venkateshwarlu, B. Swathi, Sharada. N, P. Laxmi. S. Changes of Life Style Prevent Heart Stroke, Kidney Failure, Paralysis. Asian J. Pharm. Res. 2015; 5(1): 48-50.

40. Nilima Thombre, Madhura Thete, Pranali Shimpi. Review on Role of Herbs in Management of Oral diseases. Asian J. Pharm. Res. 2020; 10(4): 321-326.

41. Soumesh Kumar Tripathy. Pharmaceutical Validation: A Quality Maintaining Tool for Pharmaceutical Industry. Asian J. Pharm. Res. 2020; 10(4):307-311.

42. Shivani Sharma, Manpreet Rana, Hitesh Kumar, Bharat Parashar. It’s era to move towards nature for getting beneficial effects of plants having Antioxidant activity to fight against deleterious diseases. Asian J. Pharm. Res. 2013; 3(2); 103-106.

43. Thresia CU, Thankappan KR, Nichter M. The need for cessation of tobacco use among patient with tuberculosis in Kerala, India. Natl Med J India. 2009; 22: 333.

44. International Institute for Population Sciences (IIPS), Mumbai. Global Adult Tobacco Survey India (GATS India), 2009- 2010. New Delhi; Ministry of Health and Family Welfare, Government of India; 2010.

45. Deepak KG, Daivadanam M, Pradeepkumar AS, Mini GK, Thankappan KR, Nichter M. Smokeless tobacco use among Tuberculosis patients in Karnataka, India: The need for cessation services. Natl Med J India. 2012; 25: 142-5.

Received on 02.04.2025 Revised on 13.06.2025

Accepted on 11.08.2025 Published on 02.01.2026

Available online from January 05, 2026

Asian J. Res. Pharm. Sci. 2026; 16(1):47-52.

DOI: 10.52711/2231-5659.2026.00008

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.